Quick Answer
Cartesian Therapeutics, Inc. reported Revenue (ASC 606) of $400.0 thousand for fiscal year 2025.
Cartesian Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $400.0K | -99.0% |
| 2024 | $38.27M | +47.2% |
| 2023 | $26.00M | -76.5% |
| 2022 | $110.78M | +30.2% |
| 2021 | $85.08M | +412.6% |
| 2020 | $16.60M | +148.6% |
| 2019 | $6.68M | +639.4% |
| 2018 | $903.0K | +336.2% |
| 2017 | $207.0K | -97.4% |
| 2016 | $8.08M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | — | — |
| June 30, 2025 | $0.00 | -100.0% | -100.0% |
| March 31, 2025 | $400.0K | -93.2% | — |
| September 30, 2024 | $0.00 | -100.0% | -100.0% |
| June 30, 2024 | $33.27M | +533.9% | +469.7% |
| March 31, 2024 | $5.84M | -1.7% | -10.9% |
| September 30, 2023 | $6.55M | -68.4% | +24.8% |
| June 30, 2023 | $5.25M | -86.6% | -11.6% |
- Cartesian Therapeutics, Inc. showed a decrease of -99.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, Cartesian Therapeutics, Inc.’s revenue (asc 606) has declined by 95.1% (from $8.08 million to $400.0 thousand).
- The most recent figure is from Cartesian Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: